Mirum Pharmaceuticals, Inc.

Associate Director, International Medical Affairs

Mirum Pharmaceuticals, Inc.  •  Zug, CH (Hybrid)  •  15 days ago
Apply
AI can make mistakes so check important info. Chat history is never stored.

Job Description

MISSION

Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.

This position reports to the Head of International Medical Affairs and is responsible of conceiving, planning and implementing the medical affairs tactics in the assigned therapeutic area. He/she will also contribute to establish the international medical strategy through cross functional interaction, in alignment with medical leads in the Countries and sitting in the Global medical Affairs Team (GMAT). He/she will lead the scientific initiatives within the European countries that Mirum directly supports and with our distributor partners.

JOB FUNCTIONS/RESPONSIBILITIES

  • Coordinate the international medical plan development and execution for the assigned area, ensuring consistency with the country level plans and with the GMAT.
  • Lead the development of scientific symposia at congresses and other medical education initiatives
  • Plan and execute EU congress related medical activities: KOL engagement, advocacy engagement, scientific booths in alignment with product strategy
  • Organize and support scientific advisory boards
  • Present scientific data at key congresses and provide input/feedback into final congress presentations.
  • Represent Int Med Affairs in EU PAG engagement/ advocacy; collaborate with and support Int PAG strategy and develop/ execute related tactics
  • Support commercial on various tactics (e.g. EU and Global Brand Plans and commercial training).
  • Support distributors markets on medical strategy, scientific education and contribute to country visits as appropriate
  • Support externally sponsored research (ESR) and Phase IV studies assessment to ensure strategic alignment and scientific and methodologic robustness.
  • Support and collaborate with relevant cross-functional International and local stakeholders such as but not limited to market-access, clinical development/ operations

QUALIFICATIONS

Education /Experience:

  • Medical Degree, Bachelor’s, Master’s, or Doctorate (i.e. RN, BS/BA, MS/MA, PharmD) level of degree from an accredited university/program.
  • 10+ years of biopharmaceutical experience, with an understanding of the current regulatory and compliance environment for prelaunch and postlaunch initiatives for an investigational asset.

Knowledge, Skills and Abilities:

  • Highly organized individual, who possesses the ability to work in a fast-paced agile environment.
  • Ability to interact externally and internally to support global business strategy across assets and launches.
  • Ability to coordinate matrix working groups operating across multiple geographies, roles and backgrounds.
  • Must possess excellent oral and written communication skills.
  • Team player with a hands-on / can-do mindset
  • Ability to interact with and coordinates appropriate scientific and medical activities with internal stakeholders (i.e. commercial, clinical operations, statistics, regulatory, publications, chemistry, manufacturing, controls ‘CMC’ etc.) as they relate to on-going medical affairs projects.
  • Ability to work independently with limited supervision and guidance.
  • Sound judgment within well-defined practices and policies.
  • Ability to manage budget for assigned projects.
  • Clinical experience/research background or knowledge in one of following areas: liver diseases, metabolic diseases or pediatrics is preferred.
  • Proficient in Microsoft OneNote, Teams and Office 365 (proficiency with Microsoft PowerPoint and Excel is essential).

Work Environment:

  • This is a high growth, fast paced organization. The ability to be productive and successful in this work environment is critical.
  • Willingness and ability to travel domestically and internationally is required; it is anticipated that this will be 40% of work time.

#LI-HYBRID

Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.

Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.

Mirum Pharmaceuticals, Inc.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.

Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.

Industry
Chemicals & Materials
Company Size
201-500 employees
Headquarters
Foster City, CA
Year Founded
2018
Social Media